Dallas, Texas, United States The main department of described VC is located in the Dallas. The company was established in North America in United States.
Among the most popular portfolio startups of the fund, we may highlight ITeos Therapeutics, TCR2. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - Belgium. Among the most successful fund investment fields, there are Medical, Medical Device.
The standard case for the fund is to invest in rounds with more than 10 partakers. Despite the curative ventures, startups are often financed by The Column Group, Remeditex Ventures, UBS Asset Management. The meaningful sponsors for the fund in investment in the same round are MPM Capital, 6 Dimensions Capital, Vida Ventures.
The top amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. This curative ventures works on 38 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. The common things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
Besides them, we counted 1 critical employee of this fund in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Brookwood Financial Partners | Beverly, Massachusetts, United States |
| Chengdu Kunde Touzi | Chengdu, China, Sichuan |
| Columbia Venture Competition | - |
| High Ground Capital | Beijing, Beijing, China |
| Huazhang Universe Media Investment Holding Group | China, Guangdong, Jiangxi |
| OJIT Ventures Investment | Islas Baleares, Palma De Mallorca, Spain |
| Optidob | Bloemendaal, Noord-Holland, The Netherlands |
| Picea Capital | Germany, Hamburg |
| Qatar Science & Technology Park | Ad Dawhah, Doha, Qatar |
| Qiuling Capital | Beijing, Beijing, China |
| Shenzhen Sidu Kongjian Touzi Co., Ltd. | China, Guangdong, Shenzhen |
| Socomore Ventures | - |
| Talis Capital | England, London, United Kingdom |
| The Linhui Fund | Changning, China, Shanghai |
| The Panther Opportunity Fund | Chicago, Illinois, United States |
| Tokyo Ohka Kogyo | Japan, Kanagawa Prefecture, Kawasaki |
| Traverse Venture Partners | District of Columbia, United States, Washington |
| Worldpay | England, London, United Kingdom |
| Yuanning Huizhi Investment Management | China, Hangzhou, Zhejiang |
| Zhuhai Keming | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ITeos Therapeutics | $75M | 20 Jun 2018 | Cambridge, Massachusetts, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ITeos Therapeutics | $75M | 20 Jun 2018 | Cambridge, Massachusetts, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States |
